Antibody-based proteomics to study cellular signalling networks

The complexity of drug discovery faces many challenges; principally, the failure of drug candidates during the development process as a result of adverse effects or lack of efficacy. A key reason for this high attrition rate is that we are only just beginning to understand the complexity of the response(s) from a biological system to perturbations, such as a disease state or drug treatment. Subsequently, a deeper insight into the molecular mechanisms underlying both disease processes and drug action will ultimately contribute to increased productivity through the drug discovery process.

Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive

Click here to join